ロード中...
Development of luspatercept to treat ineffective erythropoiesis
Luspatercept (Reblozyl) was recently approved for treating patients with transfusion-dependent lower-risk myelodysplastic syndrome (MDS) with ring sideroblasts (RS) and/or SF3B1 mutation who were not eligible for erythropoiesis-stimulating agents (ESAs) or patients for whom those agents failed. Lusp...
保存先:
| 出版年: | Blood Adv |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7948289/ https://ncbi.nlm.nih.gov/pubmed/33687432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002177 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|